Lebwohl, M.; Bachelez, H. .; Gordon, K.; Wu, T.; Chen, M.; Kaplan, B.; Papp, K. Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. J of Skin 2023, 7, s258.